跳至主要内容
临床试验/NL-OMON22399
NL-OMON22399已完成不适用

A Phase I/II study of clofarabine in combination with cytarabine and liposomal daunorubicin in children with relapsed/refractory pediatric AML.

Erasmus MC, Rotterdam, The Netherlands0 个研究点目标入组 28 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
28

研究概览

简要总结

/A

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. 2nd relapse of AML;
  • 2. Refractory AML in 1st relapse (defined as ≥ 20% blasts in the bone marrow after the 1st course of re-induction therapy according to the AML 2001/01 protocol);

排除标准

  • 1. Isolated extramedullary relapse, including isolated CNS-relapse;
  • 2. Symptomatic CNS leukemia in case of combined relapse;

研究者

发起方
Erasmus MC, Rotterdam, The Netherlands

相似试验

进行中(未招募)
不适用
A Phase I/II study of clofarabine in combination with cytarabine and liposomal daunorubicin in children with relapsed/refractory pediatric AML - CLARA-DNX
EUCTR2009-009457-13-ATErasmus MC28
进行中(未招募)
1 期
This study aims to investigate the safety and efficacy of clofarabine, given in combination with cytarabine and liposomal daunorubicin, in the treatment of children with relapsed/refractory acute myeloid leukemia (AML)
EUCTR2009-009457-13-DEErasmus MC34
进行中(未招募)
不适用
This study aims to investigate the safety and efficacy of clofarabine, given in combination with cytarabine and liposomal daunorubicin, in the treatment of children with relapsed/refractory acute myeloid leukemia (AML)Relapsed/refractory acute myeloid leukemiaMedDRA version: 14.0Level: LLTClassification code 10066638Term: Acute myeloid leukemia progressionSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10060558Term: Acute myeloid leukemia recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2009-009457-13-NLErasmus MC28
进行中(未招募)
不适用
A Phase I/II study of clofarabine in combination with cytarabine and liposomal daunorubicin in children with relapsed/refractory pediatric AML - CLARA-DNXRelapsed/refractory acute myeloid leukemiaMedDRA version: 12.0Level: LLTClassification code 10060558Term: Acute myeloid leukemia recurrentMedDRA version: 12.0Level: LLTClassification code 10066638Term: Acute myeloid leukemia progression
EUCTR2009-009457-13-CZErasmus MC28
进行中(未招募)
1 期
A Phase I/II study of clofarabine in combination with cytarabine and liposomal daunorubicin in children with relapsed/refractory pediatric AML - CLARA-DNXRelapsed/refractory acute myeloid leukemiaMedDRA version: 9.1Level: LLTClassification code 10060558Term: Acute myeloid leukemia recurrentMedDRA version: 9.1Level: LLTClassification code 10066638Term: Acute myeloid leukemia progression
EUCTR2009-009457-13-FRHospices Civils de Lyon34